According to Zacks, “DICE Therapeutics Inc. is a biopharmaceutical company. Its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. DICE Therapeutics Inc. is based in SOUTH SAN FRANCISCO, Calif. “
DICE Therapeutics stock traded down $0.65 during trading hours on Monday, reaching $17.05. The company had a trading volume of 269,417 shares, compared to its average volume of 327,925. The company has a debt-to-equity ratio of 0.01, a current ratio of 20.75 and a quick ratio of 20.75. The company has a 50-day moving average price of $18.97 and a 200 day moving average price of $21.22. DICE Therapeutics has a 12-month low of $13.39 and a 12-month high of $40.50.
Institutional investors have recently made changes to their positions in the business. Strs Ohio purchased a new position in DICE Therapeutics in the 4th quarter worth approximately $80,000. Suvretta Capital Management LLC purchased a new position in DICE Therapeutics in the 3rd quarter worth approximately $13,428,000. RA Capital Management L.P. purchased a new position in DICE Therapeutics in the 3rd quarter worth approximately $170,592,000. Janus Henderson Group PLC bought a new stake in shares of DICE Therapeutics in the 3rd quarter worth approximately $58,627,000. Finally, Tudor Investment Corp Et Al bought a new stake in shares of DICE Therapeutics in the 3rd quarter worth approximately $2,750,000. 82.91% of the stock is currently owned by institutional investors and hedge funds.
About DICE Therapeutics (Get Rating)
DICE Therapeutics, Inc, a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE, is designed to discover selective oral small molecules to modulate protein-protein interactions (PPIs) as effectively as systemic biologics.
- Get a free copy of the StockNews.com research report on DICE Therapeutics (DICE)
- Under Armor Stock is Getting Undervalued
- Palo Alto Networks Bottoms But A Rebound May Not Be Coming
- Stock Market Downgrades Are Dragging The S&P 500 Lower
- Time to Ring the Register on Funko Stock
- The Institutions Go Long Saia, Inc In Q2
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for DICE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DICE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.